Roth Capital Starts Bluebird Bio (BLUE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BLUE Hot Sheet
Price: $4.97 --0%
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
Roth Capital initiated coverage on Bluebird Bio (NASDAQ: BLUE) with a Buy rating and a price target of $50.00.
For an analyst ratings summary and ratings history on Bluebird Bio click here. For more ratings news on Bluebird Bio click here.
Shares of Bluebird Bio closed at $36.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- H.C. Wainwright Starts Kardigan Inc (KARD) at Buy
- Roth/MKM Starts Zedcor Inc (ZDC:CN) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
